Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12619948 | 0.79 | MEN1 (0.35) | MEN1KMT2AHTTBACE1KDM4E | |
| SCHEMBL10975587 | 0.71 | — | — | |
| SCHEMBL24248562 | 0.70 | SMN1; SMN2 (0.36) | SMN1; SMN2NPC1RAB9ASOAT1 | |
| SCHEMBL18119745 | 0.69 | SMN1; SMN2 (0.54) | MEN1KMT2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL18119744 | 0.68 | SMN1; SMN2 (0.62) | MEN1KMT2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL8608558 | 0.67 | MEN1 (0.69) | MEN1KMT2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL18527253 | 0.66 | — | — | |
| SCHEMBL19514190 | 0.65 | NPC1 (0.42) | MEN1KMT2AHTTSMN1; SMN2NPC1 | |
| SCHEMBL24022680 | 0.65 | SMN1; SMN2 (0.42) | MEN1KMT2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL11402954 | 0.64 | QDPR (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3453707-B1 | BENZAZEPINE DERIVATIVE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHANGHAI DE NOVO PHARMATECH CO LTD (CN) | 2022-02-16 | — | — | EP | disclosed |
| US-10669252-B2 | Benzazepine derivative, preparation method, pharmaceutical composition and use thereof | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2020-06-02 | — | — | US | disclosed |
| US-20190152941-A1 | BENZAZEPINE DERIVATIVE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2019-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10669252-B2 | Benzazepine derivative, preparation method, pharmaceutical composition and use thereof | TLR8, TLR1, TLR5 | MEN1 2449/4885KMT2A 751/4885HTT 4512/4885 |
| US-20190152941-A1 | BENZAZEPINE DERIVATIVE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | TLR8, TLR1, TLR5 | MEN1 2449/4885KMT2A 751/4885HTT 4512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.